Therapeutic Asset Ratings
130 results matching 1 filter
133,990 assets · 8,802 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Fluzoparib
HER2 positive breast carcinoma
Fudan University
P2
CCC
(48)
Gsk 5733584
HER2 positive breast carcinoma
QuantumLeap Healthcare Collaborative
P2
CCC
(48)
Her-2 Pulsed Dc1
HER2 positive breast carcinoma
H. Lee Moffitt Cancer Center and Research Institute
P2
CCC
(48)
Hrs-4508
HER2 positive breast carcinoma
Fudan University
P2
CCC
(48)
Hrs-6209
HER2 positive breast carcinoma
Fudan University
P2
CCC
(48)
IMMUNOGLOBULIN G4, ANTI-(HUMAN PROGRAMMED CELL DEATH PROTEIN 1) (HUMAN MONOCLONAL REGN2810 HEAVY CHAIN), DISULFIDE WITH HUMAN MONOCLONAL REGN2810 .KAPPA.-CHAIN, DIMER
HER2 positive breast carcinoma
QuantumLeap Healthcare Collaborative
P2
CCC
(48)
Inavolisib
HER2 positive breast carcinoma
GBG Forschungs GmbH
P2
CCC
(48)
Ivonescimab
HER2 positive breast carcinoma
Fudan University
P2
CCC
(48)
js207
HER2 positive breast carcinoma
Fudan University
P2
CCC
(48)
Lasofoxifene
HER2 positive breast carcinoma
QuantumLeap Healthcare Collaborative
P2
CCC
(48)
LEUPROLIDE
HER2 positive breast carcinoma
Fudan University
P2
CCC
(48)
Margetuximab
HER2 positive breast carcinoma
MedSIR
P2
CCC
(48)
Metformin
HER2 positive breast carcinoma
Qamar Khan
P2
CCC
(48)
Mitoxantrone
HER2 positive breast carcinoma
Fudan University
P2
CCC
(48)
N-DESMETHYL-4-HYDROXYTAMOXIFEN
HER2 positive breast carcinoma
QuantumLeap Healthcare Collaborative
P2
CCC
(48)
NEBIVOLOL
HER2 positive breast carcinoma
Ain Shams University
P2
CCC
(48)
Parstuzumab
HER2 positive breast carcinoma
Henan Cancer Hospital
P2
CCC
(48)
Pexidartinib
HER2 positive breast carcinoma
QuantumLeap Healthcare Collaborative
P2
CCC
(48)
Rilvegostomig
HER2 positive breast carcinoma
QuantumLeap Healthcare Collaborative
P2
CCC
(48)
Rivoceranib
HER2 positive breast carcinoma
Fudan University
P2
CCC
(48)
Sarilumab
HER2 positive breast carcinoma
QuantumLeap Healthcare Collaborative
P2
CCC
(48)
Shr-4602
HER2 positive breast carcinoma
Fudan University
P2
CCC
(48)
Shr-A1921
HER2 positive breast carcinoma
Fudan University
P2
CCC
(48)
Tislelizumab
HER2 positive breast carcinoma
Tianjin Medical University Cancer Institute and Hospital
P2
CCC
(48)
tqb2868
HER2 positive breast carcinoma
Fudan University
P2
CCC
(48)
Showing 76 to 100 of 130 assets
Previous
Page 4 of 6
Next